Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study
Authors:
- Michael Hecht OlsenMOMichael Hecht Olsen
- Kristian WachtellKWKristian Wachtell
- Gareth BeeversGBGareth Beevers
- Björn DahlöfBDBjörn Dahlöf
- Giovanni de SimoneGSGiovanni de Simone
- Richard B DevereuxRDRichard B Devereux
- Ulf de FaireUFUlf de Faire
- Frej FyhrquistFFFrej Fyhrquist
- Hans IbsenHIHans Ibsen
- Sverre E KjeldsenSKSverre E Kjeldsen
- Ole Lederballe-PedersenOLOle Lederballe-Pedersen
- Lars H LindholmLLLars H Lindholm
- 1 March 2009
- journal article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 27 (3) , 567-574
Abstract
Beta-blockers and angiotensin II receptor blockers have different effects on lipids. We examined lipid levels in the Losartan Intervention For Endpoint reduction in hypertension study and their impact on the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke. We measured total and high-density lipoprotein cholesterol at baseline and annually during 4.8 years of losartan-based compared with atenolol-based treatment in 8611 patients with hypertension and left ventricular hypertrophy. Patients randomized to losartan-based or atenolol-based treatment had similar baseline total (6.04 ± 1.12 vs. 6.05 ± 1.13 mmol/l, NS) and high-density lipoprotein (HDL) cholesterol (1.50 ± 0.44 vs. 1.49 ± 0.44 mmol/l, NS). Total cholesterol decreased significantly but equally (−0.37 ± 1.05 vs. −0.34 ± 1.09 mmol/l, NS), whereas HDL cholesterol decreased less during the first 2 years in patients randomized to losartan compared with atenolol (−0.13 ± 0.24 vs. −0.19 ± 0.25 mmol/l) and remained higher each year (1.38, 1.37, 1.42, 1.47, and 1.48 mmol/l vs. 1.32, 1.30, 1.36, 1.40, and 1.42 mmol/l, all P < 0.001) independent of hydrochlorothiazide or statin treatment. In Cox regression analysis, baseline total cholesterol [hazard ratio (HR) = 1.08 (1.02–1.14) per mmol/l, P < 0.01], HDL cholesterol [HR = 0.56 (0.48–0.66) per mmol/l, P < 0.001], and treatment allocation [HR = 0.86 (0.76–0.98), P < 0.05] predicted composite endpoint independently. Using time-varying analyses, the predictive strength of HDL cholesterol was increased [HR = 0.36 (0.30–0.44) per mmol/l, P < 0.001], whereas that of total cholesterol [HR = 1.03 (0.97–1.09) per mmol/l, NS] and treatment allocation [HR = 0.91 (0.80–1.03), NS] were reduced. Losartan blunted the decrease in HDL cholesterol during antihypertensive treatment in the LIFE study. Higher intreatment HDL cholesterol was associated with fewer composite endpoints and may partly explain the better outcome of losartan-based treatment.Keywords
This publication has 38 references indexed in Scilit:
- Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)The Lancet, 2005
- Effect of Antihypertensive Treatment on PlasmaFibrinogen and Serum HDL Levelsin Patients with Essential HypertensionClinical and Applied Thrombosis/Hemostasis, 2005
- Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind studyClinical Therapeutics, 2004
- High Density-Lipoprotein Subfractions of Patients Using Cardio-Selective Beta-BlockersCardiovascular Drugs and Therapy, 2002
- Diuretics and β-Blockers Do Not Have Adverse Effects at 1 Year on Plasma Lipid and Lipoprotein Profiles in Men With HypertensionArchives of internal medicine (1960), 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Effects of β-blockers on the Concentration and Oxidizability of Plasma LipidsClinical Science, 1998
- The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivityJournal Of Hypertension, 1996
- Mechanisms of Action of Adrenergic Receptor Blockers on Lipids During Antihypertensive Drug TreatmentThe Journal of Clinical Pharmacology, 1993
- Effect of Antihypertensive Drugs on Insulin, Glucose, and Lipid MetabolismDiabetes Care, 1991